The patent litigation relates to the companies’ continuous glucose monitor (CGM) technologies. Abbott and Dexcom are two leaders in the CGM space. They offer market-leading platforms, with Abbott’s FreeStyle Libre 3 and Dexcom’s G7 representing their latest-generation technologies.
News of the settlement comes within a few weeks of a Unified Patent Court decision that sided with Abbott following a CGM patent infringement claim from Dexcom. Dexcom requested that the court find infringement with the LibreLinkUp remote analyte monitoring system. The court revoked EP282 in its entirety across the contracting member states in Europe as specified by Abbott’s request. It dismissed all of Dexcom’s infringement claims based on the patent at issue.
In a news release, Abbott said the agreement to settle results in the dismissal of all pending cases in courts and patent offices worldwide. It also includes a provision that the parties will not litigate patent, trade dress, and design rights disputes with each other for the next 10 years.
The settlement includes no financial payments from either company. The company said details of the settlement remain confidential.
“Abbott considers this agreement a positive development, as it allows the company to fully focus on supporting people with diabetes with its technologies and services,” the company said in its release.
